Caitlin D. Lowery

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler et al. · Clinical Cancer Research · 2018 · 79 citations · Full text

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma

Caitlin D. Lowery, Alle B. VanWye, Michele Dowless et al. · Clinical Cancer Research · 2017 · 65 citations · Full text

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

Michele Dowless, Caitlin D. Lowery, Terry J. Shackleford et al. · Clinical Cancer Research · 2018 · 59 citations

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Solange Peters, Byoung Chul Cho, Alexander Luft et al. · Journal of Thoracic Oncology · 2024 · 47 citations · Full text

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

Caitlin D. Lowery, Wayne Blosser, Michele Dowless et al. · Clinical Cancer Research · 2017 · 34 citations